Evidence map›Paper›PMID 42779603›Full record

ReviewChildhood kidney diseases2026

Genome-based medicine in Korea: the Korea National Institute of Health infrastructure for precision medicine.

Hyun-Young Park

Abstract readReview
In one paragraph

Review in Childhood kidney diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hyun-Young Park1National Institute of Health, Cheongju, Republic of Korea.ORCID 0000-0002-6698-7368

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the completion of the Human Genome Project, genome-based medicine has progressed from a predominantly research-driven endeavor to a field of increasing clinical relevance. In Korea, the Korea National Institute of Health (KNIH) has played a central role in the establishment of the necessary research infrastructure that supports the secure and responsible use of genomic and clinical data. These efforts have enabled the generation of comprehensive genomic datasets representative of the Korean population and, together with the Korea Biobank Array optimized for population-specific variants, have strengthened discovery-driven research and accelerated advances in disease gene identification and risk prediction. More recently, KNIH has expanded analyses based on whole-genome sequencing data to support clinical translation, enabling more comprehensive variant detection and facilitating the application of genomic information to disease diagnosis and precision medicine research. These national genomic resources provide an important foundation for improving the diagnosis and management of genetically mediated conditions, including pediatric kidney diseases, where early etiologic diagnosis can substantially influence clinical decision-making and long-term outcomes. Further strengthening of institutional and regulatory frameworks will be essential to support routine clinical implementation and maximize the public health impact of genomics in Korea.

Indexed as

BiobankCohort studyData sharingKoreaPrecision medicine

Identifiers

PMID42779603
PMCPMC13587174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.